One of the best. Congrats Jamie Gull!

Looking for all star A player engineers to - full stack only - send me a DM of the coolest thing you have built in past 3 months!

Throw in some faster FDA pathways and suddenly we’re saving lives at scale.

Maximilian Maksutovic Atharva Vaidya and I with another banger! Also a ton of you obviously love your dogs because the number of people that filled out our long ass form + put down a deposit is heartwarming 🐕🥰

Many women in their 30s and 40s notice changes in their sleep, mood, or cycles, and never realize they’re signs of perimenopause. Understanding it early can make all the difference. Check out our latest article: playhealth.com/resources/what… #perimenopause #perimenopauserelief

Biotech is risky and expensive. If it were only risky, hot-blooded entrepreneurs would throw themselves in the fray, falling in droves until one manages to actually make the world a better place. If it were only expensive, silver-haired financiers would gather round long tables

Our perimenopause care platform is live today! Women deserve the right tools to navigate perimenopause into menopause - we built them and today women across the US can better understand their health and make decisions using their own data.

Introducing Odyssey—the largest and most performant protein language model ever created. Odyssey enables scientists and researchers to generate and edit proteins, the workhorses of all life on this planet, towards specific functional ends—scaled to over 102 billion parameters.

The Anthrogen team (Y Combinator S24) just launched Odyssey — a 102B-parameter protein language model and one of the most impressive examples I've seen of what tiny, focused teams can achieve in AI × biology. Anthrogen is a team of six, and they just raised seed funding

In 2020, I applied to Y Combinator with Known Medicine (S20) and had what I believed was a once in a lifetime experience to build with phenomenal peers and mentors. Fast forward 5+ years and I'm excited to be back building Play Health (F25), with more experience and

I suspect the limits of what 'a guy in his garage' is capable of in 2025 is way, way more than anyone realizes.

A tiny AI startup in Boston that sold for $500M in 2018 is the unlikely place 6 founders of near unicorns came from: — OpenEvidence [$6B]: Daniel Nadler — Surge [$25B]: Andrew Maubossin (CTO) — Langchain [$1.25B]: Harrison Chase — Suno [$1B+]: Mikey Shulman — Thinking Machines

In the YC S14 batch, Paul Buchheit and I led a group office section that included Oklo and rigetti, as well as Helion. Building a meaningful startup is more common than expected if your bet on the future is accurate + you have staying power. Still early innings for these.

1/🚨WOW! Novartis just announced that it is acquiring Avidity Biosciences and its entire new class of pioneering RNA therapeutics called Antibody Oligonucleotide Conjugates (AOCs) for the treatment of neuromuscular diseases. $NVS will pay $72 per $RNA share in cash - representing

The best cofounder pairing isn’t technical + business. It’s technical + technical

Anthropic just grew from $1B to $7B in annualized revenue in 9 months. Unprecedented for a startup to grow that fast at that scale. We made an exception when Pioneer Fund invested in Anthropic back in 2023. We saw they could become a Trillion dollar company and that many of

I'm 24, dropped out of Duke, joined YC, and bet everything on a startup. Here's what actually happens when you go all-in: 1. Your co-founder relationship matters more than your product: You can pivot products. You can't pivot people. Most startups die from founder breakups, not

Congratulations to Giga on the $61M Series A led by Redpoint and the huge partnership with DoorDash!

Today, BillionToOne went public, becoming YC's 4th biotech IPO. As a company that quietly provides societally important infrastructure, BillionToOne is less well known than they deserve to be. Here is their story, from grad students to IPO. BillionToOne is the rare company

A scientific first! ANGPTL3 in vivo gene editing in a ph1 trial is feasible & appears to lower LDL-C by 50% and TGs by 55% among individuals with resistant hyperlipidemia. nejm.org/doi/full/10.10… NEJM #AHA25 Efficacy appears similar to zodasiran (ANGPTL3 siRNA)